Le marché mondial de l'édition du génome devrait croître à un TCAC de plus de 18,5 % entre 2021 et 2029. Il devrait atteindre plus de 14,56 milliards USD d'ici 2029, contre 3,25 milliards USD en 2020.
Le marché de l'édition du génome désigne le marché des technologies et des produits liés à l'édition du génome, une méthode précise permettant d'apporter des modifications spécifiques à l'ADN d'une cellule ou d'un organisme. Les techniques d'édition du génome, telles que CRISPR -Cas9, TALEN et les nucléases à doigt de zinc, permettent aux scientifiques de modifier la séquence d'ADN des organismes avec une précision sans précédent. Ces technologies ont de nombreuses applications dans divers domaines, notamment l'agriculture, la santé, la biotechnologie et la recherche. Dans l'agriculture, l'édition du génome peut être utilisée pour développer des cultures avec un rendement amélioré, une meilleure résistance aux maladies et une meilleure tolérance aux stress environnementaux. Dans le domaine de la santé, l'édition du génome est prometteuse pour le traitement des troubles génétiques, du cancer et des maladies infectieuses en corrigeant ou en modifiant les gènes responsables de maladies.
L’expansion du marché est principalement due à la demande croissante de gènes synthétiques et à l’adoption généralisée de la technologie d’édition du génome CRISPR dans divers secteurs de la biotechnologie. En outre, la croissance prévue devrait être stimulée par l’augmentation du financement public, l’augmentation de la production de cultures génétiquement modifiées et l’augmentation des projets de génomique.
La croissance du marché est stimulée par des réglementations gouvernementales favorables concernant la biologie synthétique, une demande accrue de gènes et de cellules modifiés et des investissements accrus des organismes gouvernementaux et des grandes entreprises. De plus, la découverte et l'application de techniques d'édition génétique non conventionnelles à des fins thérapeutiques représentent une avancée significative dans la thérapie génique et la biologie moléculaire, contribuant ainsi à l'expansion du marché.
En outre, la disponibilité de systèmes de thérapie génique conviviaux, les avancées en matière d’ingénierie du génome et le potentiel de la thérapie génique pour faciliter des analyses rapides de la fonction des gènes à l’échelle du génome contribuent tous à la croissance du marché tout au long de la période de prévision.
On the basis of technology type, the global genome editing market has been segmented as – CRISPR, Talen, ZFN, and other genome editing or genetic editing technologies. CRISPR is a powerful tool for editing genomes, denotation it allows researchers to easily modify DNA sequences and change gene function. It has many potential applications, including amending genetic defects, treating and preventing the spread of diseases, and improving the growth and resilience of crops.
Talen can be used to edit genomes by encouraging double-strand breaks (DSB), which cells respond to with repair mechanisms. Non-homologous end joining (NHEJ) directly ligates DNA from either side of a double-strand break where there is very slight or no sequence overlap for annealing. Zinc Finger Nucleases (ZFNs) are a class of engineered DNA-binding proteins that enable targeted editing of the genome by creating double-strand breakdowns in DNA at user-specified locations. The other technologies category includes antisense technology and mega nucleases.
Based on application, the genome editing market is divided into five segments, gene therapy, disease models, functional genomics, knockdown/activation and other applications. Genetic engineers have developed genetic recombination techniques or genome editing techniques to manipulate gene sequences in plants, animals and other organisms to express specific traits. Applications for genetic editing are increasing as engineers and scientists work together to identify the locations and functions of specific genes in the DNA sequence of various organisms.
A laboratory method that is used to determine the entire genetic makeup of a specific organism or cell type. This method can be used to find changes in areas of the genome. These changes may help scientists understand how specific diseases form. Functional genomics involves learning the expression and function of the genome. Genomics can also comprise the investigation of interactions between genes and between genes and the environment.
End user segment of the global genome editing market includes academic & government research institutes, biotechnology & pharmaceutical companies, contract research organizations, and other end users. Biotechnology and pharmaceutical companies are one of the major end users of the genome editing market. These companies are incorporating numerous CRISPR gene editing products and services for the treatment and screening of genetic disorders. Gene therapy holds potential for treating a wide range of diseases, such as cancer, cystic fibrosis, heart disease, diabetes, hemophilia and AIDS.
Abcam, Inc., is one of the emerging players in the CRISPR gene editing market. The global life sciences company develops biological reagents and tools required in drug discovery, basic research, diagnostics, and other fields and applications. The company offers research-based only proteomic tools, antibodies, protein binding reagents, and immunoassays to researchers and scientists in academic institutes, biotechnology, diagnostics, and pharmaceuticals companies for studying biological pathways critical in scientific research, drug discovery, and diagnostics.
Applied StemCell, Inc., headquartered in California, US, is one of the emerging private players in the gene editing market. The company develops gene modification technologies enabling stem cell and genome editing to augment revolutionary biomedical and industrial research and applications. The company’s competitors that cater to the CRISPR gene editing market include System Biosciences LLC, Horizon Discovery Group PLC, Takara Bio, GeneCopoeia, Inc., and Cellecta, Inc., among others.
The genome editing market by region includes North America, Europe, Asia-Pacific (APAC), South America, and Middle East & Africa (MEA). The North America region is currently dominating the global genome editing market. Several conglomerate and small-medium enterprises are focused on collaborating with each other and other distributing channels to expand their global reach by developing more cost-effective and advanced products is consequentially promoting the growth of the global genome editing market.
Want to know more about the report or any specific requirement?
We asked them to research ‘ Equipment market’ all over the world, and their whole arrangement was helpful to us. thehealthanalytics.com insightful analysis and reports contributed to our current analysis and in creating a future strategy. Besides, the te
We asked them to research ‘Equipment market’ all over the world, and their whole arrangement was helpful to us. thehealthanalytics.com insightful analysis and reports contributed to our current analysis and in creating a future strategy. Besides, the te
Our Report’s database covers almost all topics of all regions over the Globe.
Tie ups with top publishers around the globe.
Complete pre and post sales support.
Complete secure payment process.